Free Trial

Alpha Pro Tech (APT) Competitors

$4.87
-0.07 (-1.42%)
(As of 06/7/2024 ET)

APT vs. INGN, LAKE, CLGN, NTRB, MLSS, COCH, RBOT, LFWD, POAI, and HSCS

Should you be buying Alpha Pro Tech stock or one of its competitors? The main competitors of Alpha Pro Tech include Inogen (INGN), Lakeland Industries (LAKE), CollPlant Biotechnologies (CLGN), Nutriband (NTRB), Milestone Scientific (MLSS), Envoy Medical (COCH), Vicarious Surgical (RBOT), ReWalk Robotics (LFWD), Predictive Oncology (POAI), and Heart Test Laboratories (HSCS). These companies are all part of the "surgical appliances & supplies" industry.

Alpha Pro Tech vs.

Inogen (NASDAQ:INGN) and Alpha Pro Tech (NYSE:APT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.

In the previous week, Alpha Pro Tech had 2 more articles in the media than Inogen. MarketBeat recorded 2 mentions for Alpha Pro Tech and 0 mentions for Inogen. Alpha Pro Tech's average media sentiment score of 0.00 beat Inogen's score of -0.45 indicating that Inogen is being referred to more favorably in the media.

Company Overall Sentiment
Inogen Neutral
Alpha Pro Tech Neutral

Alpha Pro Tech has a net margin of 6.92% compared to Alpha Pro Tech's net margin of -30.07%. Inogen's return on equity of 6.86% beat Alpha Pro Tech's return on equity.

Company Net Margins Return on Equity Return on Assets
Inogen-30.07% -42.87% -28.44%
Alpha Pro Tech 6.92%6.86%6.23%

Alpha Pro Tech has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Alpha Pro Tech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$315.66M0.65-$102.45M-$4.15-2.08
Alpha Pro Tech$61.23M0.93$4.19M$0.3613.53

Inogen presently has a consensus target price of $7.00, indicating a potential downside of 18.98%. Given Alpha Pro Tech's higher possible upside, research analysts plainly believe Inogen is more favorable than Alpha Pro Tech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Alpha Pro Tech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Inogen received 373 more outperform votes than Alpha Pro Tech when rated by MarketBeat users. However, 100.00% of users gave Alpha Pro Tech an outperform vote while only 70.44% of users gave Inogen an outperform vote.

CompanyUnderperformOutperform
InogenOutperform Votes
386
70.44%
Underperform Votes
162
29.56%
Alpha Pro TechOutperform Votes
13
100.00%
Underperform Votes
No Votes

89.9% of Inogen shares are held by institutional investors. Comparatively, 22.7% of Alpha Pro Tech shares are held by institutional investors. 1.0% of Inogen shares are held by insiders. Comparatively, 13.6% of Alpha Pro Tech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Inogen has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Alpha Pro Tech has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500.

Summary

Alpha Pro Tech beats Inogen on 10 of the 17 factors compared between the two stocks.

Get Alpha Pro Tech News Delivered to You Automatically

Sign up to receive the latest news and ratings for APT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APT vs. The Competition

MetricAlpha Pro TechSurgical appliances & supplies IndustryIndustrial SectorNYSE Exchange
Market Cap$56.93M$9.18B$9.16B$17.73B
Dividend YieldN/A1.25%2.00%3.55%
P/E Ratio13.5312.5717.4322.44
Price / Sales0.9345.089.0114.38
Price / Cash11.2521.0218.7020.21
Price / Book0.925.753.594.99
Net Income$4.19M$182.64M$462.54M$975.94M
7 Day Performance-2.60%-1.28%-2.27%-1.87%
1 Month Performance-15.30%-2.95%-2.67%-0.74%
1 Year Performance24.23%-14.71%2.31%8.66%

Alpha Pro Tech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INGN
Inogen
2.2134 of 5 stars
$8.30
+2.3%
$7.00
-15.7%
-22.6%$195.69M$315.66M-2.00834Positive News
LAKE
Lakeland Industries
4.6077 of 5 stars
$18.43
-1.3%
$22.00
+19.4%
+82.1%$135.97M$124.69M25.961,750Analyst Forecast
Analyst Revision
News Coverage
CLGN
CollPlant Biotechnologies
1.4669 of 5 stars
$5.61
+2.0%
$11.00
+96.3%
-32.0%$64.19M$10.96M-8.2475
NTRB
Nutriband
0 of 5 stars
$5.45
+7.9%
N/A+103.9%$59.79M$2.09M-7.083Gap Down
MLSS
Milestone Scientific
0 of 5 stars
$0.73
flat
N/A-29.9%$56.21M$9.83M-7.2817Gap Down
COCH
Envoy Medical
0.8573 of 5 stars
$2.37
-1.3%
$6.00
+153.2%
N/A$46.45M$320,000.000.0034News Coverage
Gap Down
RBOT
Vicarious Surgical
1.6235 of 5 stars
$0.32
+6.8%
$0.67
+111.6%
-85.4%$46.39MN/A-0.833Negative News
Gap Down
LFWD
ReWalk Robotics
2.7723 of 5 stars
$4.58
+2.2%
$13.00
+183.8%
N/A$39.40M$13.85M-1.47108Positive News
POAI
Predictive Oncology
0 of 5 stars
$1.43
-18.8%
N/A-64.5%$5.87M$1.78M-0.3934Gap Down
HSCS
Heart Test Laboratories
0 of 5 stars
$5.50
-19.2%
N/A-94.5%$3.61MN/A-0.1112Gap Down

Related Companies and Tools

This page (NYSE:APT) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners